Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Huber

Showing results (191-200 of 752) with videos related to

Pageof 76
Sort By:
European Heart Journal|May 8, 2010
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Gregory Y H Lip, Kurt Huber, Felicita Andreotti, et al.
Atherosclerosis|August 18, 2009
Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5aWalter S Speidl, Katharina M Katsaros, Stefan P Kastl, et al.
European Heart Journal. Acute Cardiovascular Care|June 9, 2017
Use of copeptin for rapid rule-out of acute myocardial infarctionChristian Mueller, Martin Möckel, Evangelos Giannitsis, et al.
JACC. Cardiovascular Interventions|February 5, 2010
Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9Katharina M Katsaros, Stefan P Kastl, Gerlinde Zorn, et al.
Thrombosis and Haemostasis|January 12, 2010
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stentingGregory Y H Lip, Kurt Huber, Felicita Andreotti, et al.
European Heart Journal. Acute Cardiovascular Care|May 10, 2017
What to do when you question cardiac troponin valuesJohannes Mair, Bertil Lindahl, Christian Müller, et al.
Archives of Medical Science : AMS|January 31, 2019
Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapyBernhard Jäger, Editha Piackova, Paul Michael Haller, et al.
Plos One|January 25, 2017
Copeptin Predicts Mortality in Critically Ill PatientsKonstantin A Krychtiuk, Maria C Honeder, Max Lenz, et al.
Clinical Chemistry|June 21, 2003
Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?Georg Endler, Ahmad Hamwi, Raute Sunder-Plassmann, et al.
International Journal of Cardiology|March 8, 2011
Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversionMatthias K Freynhofer, Rudolf Jarai, Thomas Höchtl, et al.
Pageof 76

Showing results (191-200 of 752) with videos related to

Sort By:
Pageof 76
European Heart Journal|May 8, 2010
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)Gregory Y H Lip, Kurt Huber, Felicita Andreotti, et al.
Atherosclerosis|August 18, 2009
Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5aWalter S Speidl, Katharina M Katsaros, Stefan P Kastl, et al.
European Heart Journal. Acute Cardiovascular Care|June 9, 2017
Use of copeptin for rapid rule-out of acute myocardial infarctionChristian Mueller, Martin Möckel, Evangelos Giannitsis, et al.
JACC. Cardiovascular Interventions|February 5, 2010
Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9Katharina M Katsaros, Stefan P Kastl, Gerlinde Zorn, et al.
Thrombosis and Haemostasis|January 12, 2010
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stentingGregory Y H Lip, Kurt Huber, Felicita Andreotti, et al.
European Heart Journal. Acute Cardiovascular Care|May 10, 2017
What to do when you question cardiac troponin valuesJohannes Mair, Bertil Lindahl, Christian Müller, et al.
Archives of Medical Science : AMS|January 31, 2019
Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapyBernhard Jäger, Editha Piackova, Paul Michael Haller, et al.
Plos One|January 25, 2017
Copeptin Predicts Mortality in Critically Ill PatientsKonstantin A Krychtiuk, Maria C Honeder, Max Lenz, et al.
Clinical Chemistry|June 21, 2003
Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?Georg Endler, Ahmad Hamwi, Raute Sunder-Plassmann, et al.
International Journal of Cardiology|March 8, 2011
Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversionMatthias K Freynhofer, Rudolf Jarai, Thomas Höchtl, et al.
Pageof 76